Antiparkinsonian drugs and central dopamine neurons.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002395:Catecholamines / Q000032:analysis; D003891:Desipramine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D005470:Fluorometry; D008297:Male; D009474:Neurons / Q000032:analysis / Q000187:drug effects*; D009526:Nialamide / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D014326:Tropanes / Q000494:pharmacology
D002395:Catecholamines; D010276:Parasympatholytics; D014326:Tropanes; D004295:Dihydroxyphenylalanine; D001285:Atropine; D012110:Reserpine; D009526:Nialamide; D003891:Desipramine; D004298:Dopamine